Skip to main content

Table 1 Clinical and laboratory data of patients with hematological malignancy

From: Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan

  Total AML ALL Lymphoma CML/MPN CLL MM MDS/AA p
Number 1962 606 160 769 60 27 197 143  
Gender Man 1048 326 83 399 36 16 108 81 0.799
Woman 914 280 77 370 24 11 89 62  
Age, median(range), year 55(15–97) 54(17–92) 38(16–86) 57(15–97) 48(18–86) 61(37–89) 59(30–87) 55(17–94) <0.001
HBs Ag(+) at diagnosis 286 75 13 142 6 5 31 14 0.002
HBV reactivation 97 29 3 46 1 2 10 6 0.335
HBs Ag(−) positive seroconversion 41 5 7 24 0 1 3 1 0.013
Hepatitis C 73 17 0 42 1 1 5 7 0.013
Liver cirrhosis 21 6 1 10 1 0 1 2 0.924
Hepatocellular carcinoma 9 3 0 4 2 0 0 0 0.038
Underlying diabetes 273 75 22 109 8 4 31 24 0.833
Allogeneic transplantation 439 233 81 48 18 2 3 54 <0.001
  1. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML/MPN chronic myeloid leukemia/myeloproliferative neoplasm, CLL chronic lymphocytic leukemia, MM myeloma, MDS/AA myelodysplastic syndrome/aplastic anemia